



# INTHELIA THERAPEUTICS

HARNESSING THE POWER OF CUTTING-EDGE SCIENCE AND INNOVATIVE TECHNOLOGIES TO DEVELOP AND DELIVER TRANSFORMATIVE PRECISION THERAPIES TO TREAT SERIOUS INFECTIOUS DISEASE.



## BUSINESS SUMMARY:

Sepsis is defined as a dysregulated response to infection that causes almost 50 million cases and 11 million deaths each year. Inthelia is aiming to create a paradigm shift in sepsis treatment and diagnostics with their newly discovered host targeted therapy and companion diagnostic, offering the potential for improved outcomes, reduced reliance on antimicrobials, and enhanced resilience against antimicrobial resistance.

## TEAM:



Prof Steve Kerrigan  
Chief Scientific Officer



INDUSTRY: Therapeutics  
NUMBER OF EMPLOYEES: 4  
DATE FOUNDED: 2021  
COMPANY STAGE: Preclinical

## CONTACT

Prof Steve Kerrigan  
Chief Scientific Officer  
Email: skerrigan@inthelia.com

<https://inthelia.com/>

Dr Conor MacCormack  
RCSI, Spin out Company Manager  
Email: conormaccormack@rcsi.ie

## MARKET OPPORTUNITY:


- High Incidence and Mortality Rates: Sepsis affects millions of people globally each year and has a high mortality rate, making it a critical area for medical intervention.
- Significant Healthcare Costs: Sepsis is one of the most expensive conditions to treat in hospitals, leading to significant healthcare costs. This economic burden drives demand for more effective treatments and preventative measures.
- Lack of Effective Treatments: There is currently a lack of highly effective treatments for sepsis, creating a substantial unmet medical need. Innovations in treatment can capture a large share of this market.
- Regulatory Support: There is strong regulatory support for developing new sepsis treatments, including fast-track designations and funding opportunities, which can accelerate the time to market for new therapies.

## MARKET READINES

- **Pre-Clinical Development:** Significant milestones met
- **Financial Stability:** Acquisition of more than €1M non-dilutive funding
- **Strategic Partnerships:** J&J and BARDA
- **Regulatory Pathway:** Numerous patents filed and granted

## CUTTING EDGE TECHNOLOGY:

- Having seen numerous attempts to tackle the escalating anti-microbial resistance global crisis, Inthelia believes that the solution is not more anti-microbials, but a complete paradigm shift towards a new type of drug therapy that works along side existing treatments.
- Host-Targeted Therapy [HTT] for treating infections focuses on modulating host factors or pathways that pathogens exploit to cause disease, rather than targeting the pathogens directly
- By targeting host molecules, pathways, or immune responses, HTT aims to enhance the host's ability to control or eliminate the infection, while potentially reducing the risk of resistance development by the pathogen.
- Inthelia Therapeutics' lead drug candidate, Cilengitide is a potent inhibitor of  $\alpha\text{V}\beta\text{3}$  integrin signalling, with an excellent PK and safety profile which has been shown to significantly reduce injury caused by inflammation in small and large animal models of infection. This novel, non antibiotic approach represents a promising new treatment pathway for patients with sepsis.



## INVESTMENT:

